Clinical Trials Browser

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05385926 2024-02-05

Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma

Phase 2 Unknown

34 enrolled

Head & Neck

Nasopharyngeal Neoplasms

NCT06235918 2024-02-01

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03532737 2024-01-23

Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

Phase 2 Unknown

50 enrolled

Head & Neck

Head and Neck Neoplasms

NCT03146650 2024-01-18

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Phase 2 Unknown

25 enrolled 14 charts

Head & Neck

Salivary Gland Neoplasms

NCT03708822 2024-01-18

Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 2 Unknown

48 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04398524 2024-01-16

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Phase 2 Unknown

65 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03669718 2023-12-29

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Phase 2 Unknown

194 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06170697 2023-12-20

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06156878 2023-12-05

PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Phase 2 Unknown

41 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06156891 2023-12-05

PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC

Phase 2 Unknown

60 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT06146985 2023-11-28

Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer

Phase 2 Unknown

67 enrolled

Head & Neck

Thyroid Neoplasms

NCT06107114 2023-11-22

CZCNRHNSCC

Phase 2 Unknown

52 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06142318 2023-11-21

Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

66 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06103617 2023-11-18

Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer

Phase 2 Unknown

10 enrolled

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT02624128 2023-11-13

V-CHANCE

Phase 2 Unknown

39 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT06130007 2023-11-13

B2023-153

Phase 2 Unknown

48 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03088059 2023-11-03

UPSTREAM

Phase 2 Unknown

340 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04920344 2023-11-03

Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy

Phase 2 Unknown

15 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT05182931 2023-10-31

I-FIRST

Phase 2 Unknown

80 enrolled

Head & Neck

Thyroid Neoplasms

NCT04447183 2023-10-23

DTC

Phase 2 Unknown

120 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT06081582 2023-10-13

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

Phase 2 Unknown

33 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03097939 2023-10-11

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Phase 2 Unknown

113 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05626829 2023-10-06

Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma

Phase 2 Unknown

18 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT05800834 2023-09-28

MorphineGEL

Phase 2 Unknown

106 enrolled

BreastHead & Neck

Cancer Pain, Breast Neoplasms, Head and Neck Neoplasms, Wounds and Injuries

NCT05520814 2023-09-21

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Phase 2 Unknown

50 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT06023875 2023-09-05

NCCCNRHNSCC

Phase 2 Unknown

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05658016 2023-08-14

Phase 2a Study to Evaluate Suppression of Radiotherapy-induced Mucositis by TK112690

Phase 2 Unknown

24 enrolled

Head & NeckOther

Head and Neck Neoplasms, Mucositis

NCT04156698 2023-08-09

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Phase 2 Unknown

51 enrolled

Head & Neck

Hypopharyngeal Neoplasms

NCT04297995 2023-08-08

Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

Phase 2 Unknown

131 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05981157 2023-08-08

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Phase 2 Unknown

27 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05965154 2023-07-28

Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

22 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03925090 2023-07-03

Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Phase 2 Unknown

150 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT02760667 2023-06-27

Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer

Phase 2 Unknown

20 enrolled

Head & Neck

Head and Neck Neoplasms, Laryngeal Neoplasms, Oropharyngeal Neoplasms

NCT04619316 2023-06-22

ERRITI

Phase 2 Unknown

70 enrolled

Head & Neck

Thyroid Neoplasms

NCT04072107 2023-06-18

EP-STAR

Phase 2 Unknown

110 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04221516 2023-06-18

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Phase 2 Unknown

52 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04586088 2023-05-06

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Phase 2 Unknown

58 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05229315 2023-04-13

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

Phase 2 Unknown

45 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05803915 2023-04-07

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

Phase 2 Unknown

57 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02285530 2023-04-05

GDF15 Based TPF Induction Chemotherapy for OSCC Patients

Phase 2 Unknown

72 enrolled

Head & Neck

Carcinoma, Squamous Cell, Mouth Neoplasms

NCT05790200 2023-03-30

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

Phase 2 Unknown

30 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05097209 2023-03-23

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Unknown

200 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03737968 2023-03-21

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Phase 2 Unknown

48 enrolled

Head & Neck

Laryngeal Diseases

NCT01590355 2023-03-08

ORATOR

Phase 2 Unknown

68 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Clinical Trials

Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal Cancer

VUBAR

Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC

Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer

CZCNRHNSCC

Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma

Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer

V-CHANCE

B2023-153

UPSTREAM

Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy

I-FIRST

DTC

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma

MorphineGEL

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

NCCCNRHNSCC

Phase 2a Study to Evaluate Suppression of Radiotherapy-induced Mucositis by TK112690

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma

Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer

ERRITI

EP-STAR

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

GDF15 Based TPF Induction Chemotherapy for OSCC Patients

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

ORATOR

Immunological Variables Associated to ICI Toxicity in Cancer Patients